The College of American Pathologists (CAP) has awarded accreditation to Cynvenio Biosystems Inc, Los Angeles, for its lab services. Cynvenio also holds certification under the terms of the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
During the CAP accreditation process, which is designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control procedures for the preceding two years. CAP inspectors also examine the laboratory’s staff qualifications, equipment, facilities, safety program and record, and overall management.
“Our ClearID sequencing tests for breast, prostate, and colorectal cancer have been available to international customers and oncology researchers since 2013, in part because our patient sample kits are practical and travel unrefrigerated to our processing center, and because we deliver genomic results in a week from a standard blood draw,” says André de Fusco, chief executive of Cynvenio. “The 2015 CAP accreditation gives our international partners visibility into Cynvenio’s licensure in support of our international lab service strategy, particularly in Asia and Europe.”
Cynvenio’s lab services support clinical utility studies and LiquidBiopsy sequencing programs, which can be migrated in-house upon request. LiquidBiopsy instrumentation and consumables can also be purchased globally through Cynvenio’s partnership with Thermo Fisher Scientific.
For more information, visit Cynvenio.